Highlights Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
6.48 ^USD	+2.05%		+2.37%	-23.13%

Apr. 08	Replimune Group Provides Interim Results for Skin Cancer Therapy	MT
Mar. 26	Replimune Group, Inc. Announces Management Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Replimune Group Provides Interim Results for Skin Cancer Therapy	Apr. 08	MT
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers	Dec. 05	CI
Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-03	CI
Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting	23-06-03	CI
Replimune Group's Fiscal Q4 Net Loss Widens; Chief Financial Officer Jean Franchi to Depart	23-05-18	MT
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-18	CI
Replimune's Fiscal Q3 Loss Widens; Company Sees Cash Runway to Fund Operations Into Second Half of 2025	23-02-09	MT
2015 Enterprise Management Incentive Share Option Plan	23-02-09	AQ
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
Replimune, Roche to Collaborate on Cancer Drug Development Program	22-12-07	MT
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update	22-12-07	CI
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 in Colorectal Cancer and Hepatocellular Carcinoma	22-12-07	CI
2015 Enterprise Management Incentive Share Option Plan	22-11-03	AQ
Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-03	CI
2015 Enterprise Management Incentive Share Option Plan	22-08-04	AQ
Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-04	CI
Replimune Group's Fiscal Q4 Net Loss Widens	22-05-19	MT
REPLIMUNE GROUP, INC. Management's discussion and analysis of financial condition and results of operations (form 10-K)	22-05-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Replimune Group, Inc.

Equities

REPL

US76029N1063

Highlights

Filters